广州安必平医药科技股份有限公司

Group 1 - The major shareholder, Zhuhai Gaotejia, and its associates held a total of 10,309,059 shares, accounting for 11.0178% of the company's total share capital before the reduction plan [1][2] - The reduction plan allowed for a maximum of 2,806,977 shares to be sold, representing up to 3.00% of the company's total share capital [2] - The actual reduction resulted in the sale of 2,144,897 shares, which is 2.2923% of the total share capital, completed within the disclosed timeframe [2][3] Group 2 - The equity change does not trigger a mandatory tender offer and will not alter the company's controlling shareholder or actual controller [3][5] - The reduction was consistent with the previously disclosed plan, and the minimum reduction quantity was achieved [4] - The completion of the reduction plan is expected to have no significant impact on the company's governance structure or future operations [5] Group 3 - In the first quarter of 2025, the company and its subsidiaries obtained 9 domestic medical device registration/filing certificates and 14 intellectual property qualifications [7] - The acquisition of these qualifications is expected to enhance the company's product variety and strengthen its intellectual property protection system, particularly in the fields of tumor screening and precision diagnosis [7]